BitSong (BTSG)
BitSong is a blockchain-based platform designed to empower the music industry by enabling artists to distribute their work directly to listeners, bypassing traditional intermediaries. Utilizing decentralized technology, BitSong aims to create a more equitable ecosystem where artists retain greater control over their content and revenue streams.
The platform offers features such as music streaming, fan engagement tools, and the issuance of Fan Tokens and NFTs, all powered by the BTSG token. By integrating these services, BitSong seeks to enhance the artist-fan relationship and provide new avenues for monetization within the music industry. Chart
Coinbase Global, Inc. (COIN)
Coinbase Global, Inc. operates a leading cryptocurrency exchange platform that allows users to buy, sell, and manage various digital assets. The company provides a secure and user-friendly interface catering to both retail and institutional investors, facilitating access to the evolving digital currency market.
Committed to regulatory compliance and security, Coinbase offers a range of services including custodial accounts for institutions, a trading platform for professional traders, and a wallet for individual investors. The company’s mission is to create an open financial system for the world. Chart
Rhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic disorders of obesity. Their lead product, IMCIVREE (setmelanotide), is approved for certain conditions and aims to address the underlying causes of obesity in patients with specific genetic deficiencies.
The company is dedicated to advancing the understanding of rare genetic obesity and continues to explore the potential of setmelanotide in additional indications. Rhythm Pharmaceuticals strives to improve the lives of patients through targeted therapies that address unmet medical needs. Chart
Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. is a biotechnology company specializing in the development of transformative cell and exosome-based therapies for the treatment of rare diseases. Their lead candidate, CAP-1002, is an allogeneic cell therapy in development for Duchenne muscular dystrophy and other indications.
The company’s innovative approach leverages the regenerative potential of cardiosphere-derived cells and exosome technologies to address serious medical conditions. Capricor is committed to advancing its pipeline to bring novel therapies to patients in need. Chart